Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Chn5.5
Chondroitin – Forschung
Hilft vermutlich
162 begutachtete Studien
Was die Evidenz sagt
Hilft vermutlich
Chondroitin half in etwa der Hälfte (7/12) der Studien, die einen Effekt gemessen haben — vielversprechend, aber nicht einhellig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1971–2026 mit einer typischen Studiengröße von 166 Teilnehmenden.
Basierend auf 161 Studien · 34 Meta-Analysen · 111 RCTs · 70,842 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
7geholfen2unklar3nicht geholfen· 149 weitere ohne bewertete Effektdaten
Nach Outcome
Joint pain & arthritisVerbesserter Gelenkkomfort und Knorpelunterstützung innerhalb von 8-12 Wochen · 8-12 weeks
Hilft vermutlich87 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung20 Studien
Heart & blood pressure
Überwiegend Mechanismus / Beobachtung6 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung4 Studien
InflammationMäßige Verringerung von Gelenkschmerzen und Steifheit · 8-12 weeks
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 30 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
57%
über Studien hinweg
Untersuchte Personen
71k
typische Studie: 166 Personen
Stärkste Designs
145
34 gepoolt, 111 randomisiert
Zeigte Nutzen
58%
7/12 Studien
Wie lange Studien liefen
1–4 Wochen
1
1–3 Monate
3
3+ Monate
5
Untersuchte Populationen
Patients with knee osteoarthritis5
Patients with osteoarthritis4
Knee OA patients4
Patients with hand osteoarthritis1
Stetige Forschung
30 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
197119982026
1Pain reduction in knee osteoarthritisSystematische Übersichtn=9,110 · very large study2015
Einfach gesagt: Chondroitin shows small to moderate benefit for OA pain.
Singh JA et al. · Cochrane Database of Systematic Reviews (2015)
2Safety of anti-osteoarthritis medicationsSystematische Übersichtn=22,938 · very large study2025
Einfach gesagt: This SR confirms previous evidence on the safety of anti-OA medications from meta-analyses of phase 3 RCTs.
Honvo G et al. · Drugs (2025)
This SR confirms previous evidence on the safety of anti-OA medications from meta-analyses of phase 3 RCTs.
Beyond the evidence here reported, the limitations of this research highlight the urgent need of a reporting guideline for post-marketing safety surveillance studies.
Importantly, real-life safety surveillance of anti-OA medications should be strengthened with large cohort studies with control groups, and results should be disaggregated by disease populations for drugs common to several conditions.
Einfach gesagt: Our study confirmed that the combination of glucosamine and chondroitin is effective and superior to other treatments in knee osteoarthritis to a certain extent.
Meng Z et al. · Archives of orthopaedic and trauma surgery (2023)
Our study confirmed that the combination of glucosamine and chondroitin is effective and superior to other treatments in knee osteoarthritis to a certain extent.
It is worthwhile to popularize and apply the combination in KOA treatment considering the point of effect, tolerability and economic costs.
Additionally, regarding the limited number of studies and uneven trial quality, more high-quality trials are required to investigate the accurate clinical advantages of the combination.
4Pain reduction in hand osteoarthritisMeta-Analysen=3,965 · very large study2024
Einfach gesagt: In summary, GCSB-5 and CRx-102 exhibit efficacy in alleviating pain and stiffness in HOA, respectively.
Wu R et al. · PloS one (2024)
Kein klarer Effekt
← SchlechterKein EffektBesser →
GCSB-5, a specific herbal complex that mainly regulate pain in hand osteoarthritis, showed the greatest reduction in pain [WMD = -13.00, 95% CI (-26.69, 0.69)].
CRx-102, s specific medication characterized by its significant effect for relieving joint stiffness symptoms, remarkably mitigated stiffness [WMD = -7.50, 95% CI (-8.90, -6.10)].
Chondroitin sulfate displayed the highest incidence of adverse events [RR = 0.26, 95% CI (0.06, 1.22)].
5Efficacy for osteoarthritis and joint painSystematische Übersichtn=146 · medium study2025
Einfach gesagt: Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain.
Baden KER et al. · Nutrients (2025)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Of the 2013 articles screened, 146 studies were included in our review, with nearly 60% being randomized controlled trials and most conducted in Europe, Asia, or the U.S.
Most studies focused on osteoarthritis and joint pain, with over 90% of efficacy studies reporting positive outcomes and most safety studies indicating minimal or no adverse effects.
Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain.
Einfach gesagt: The present study provided evidence for the symptomatic efficacy of glucosamine plus chondroitin in the treatment of knee OA.
Zeng C et al. · Scientific reports (2015)
All treatment options showed clinically significant improvement from baseline pain, but only glucosamine plus chondroitin showed clinically significant improvement from baseline function.
In terms of the structure-modifying effect, both glucosamine alone and chondroitin alone achieved a statistically significant reduction in joint space narrowing.
The present study provided evidence for the symptomatic efficacy of glucosamine plus chondroitin in the treatment of knee OA.
15Effectiveness and safety of SYSADOAs for knee osteoarthritisMeta-Analyse2025
Einfach gesagt: Level of Evidence: Therapeutic Level II.
Park YB et al. · Medicina (Kaunas, Lithuania) (2025)
Regarding the safety profile, the risk ratios did not differ significantly between the treatment and control groups, including the placebo and non-placebo subgroups.
Conclusions: Glucosamine, chondroitin, and SKCPT/SKI306X improved the pain and function and were non-inferior to pharmacologic drugs for up to 12 months.
These findings support the clinical use of these SYSADOAs to treat knee OA.